الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
liver disease (CLD) is considered a major health
problem worldwide; it accounts for 2 million deaths every year from
either decompensated cirrhosis or hepatocellular carcinoma (HCC). In
addition, end-stage viral hepatitis- related cirrhosis is considered the
first leading indication for liver transplantation among adults.
However, the widespread vaccination for hepatitis B virus infection
(HBV) and the antiviral treatment for both HBV and hepatitis C virus
infection (HCV) have recently changed the list of CLD’s causes
priorities. Non-alcoholic fatty liver disease (NAFLD), which is is a
spectrum of liver disease including non-alcoholic fatty liver (NAFL)
and non-alcoholic steatohepatitis (NASH) that progress to fibrosis,
end-stage cirrhosis and HCC, has replaced viral hepatitis to become
the leading cause of chronic liver disease in different countries.
Moreover, failure of obtaining sustained virological response (SVR)
after anti-viral agents is an upcoming issue which could be attributed
to secondary fat accumulation. Therefore, studies has focused on
improving the therapeutic response of anti-viral agents with a special
attention for secondary hepatic steatosis. In addition, early prevention
and treatment of NAFLD become an urgent necessity.
Farnesoid X receptor (FXR) has recently been highlighted as a
target agent in many CLDs. Previous studies have reported the role of
FXR agonists in the management of NAFLD with many ongoing
clinical trials. Similarly, some authors assumed an emerging antiviral
role of FXR agonists in patients with HCV infection. However, the
impact of FXR on NAFLD, chronic HCV infection and the
progression of liver fibrosis is a matter of controversy.